Bezafibrate lowers very long‐chain fatty acids in X‐linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
X‐linked adrenoleukodystrophy (X‐ALD) is caused by mutations in the ABCD1 gene encoding ALDP, an ATP‐binding‐cassette (ABC) transporter located in the peroxisomal membrane. ALDP deficiency results in impaired peroxisomal β‐oxidation and the subsequent accumulation of very long‐chain fatty acids (VLCFA; > C22:0) in plasma and tissues. VLCFA are primarily derived from endogenous synthesis by ELOVL1. Therefore inhibiting this enzyme might constitute a feasible therapeutic approach. In this paper we demonstrate that bezafibrate, a PPAR pan agonist used for the treatment of patients with hyperlipidaemia reduces VLCFA levels in X‐ALD fibroblasts. Surprisingly, the VLCFA‐lowering effect was independent of PPAR activation and not caused by the increase in either mitochondrial or peroxisomal fatty acid β‐oxidation capacity. In fact, our results show that bezafibrate reduces VLCFA synthesis by decreasing the synthesis of C26:0 through a direct inhibition of fatty acid elongation activity. Taken together, our data indicate bezafibrate as a potential pharmacotherapeutic treatment for X‐ALD. A clinical trial is currently ongoing to evaluate the effect in patients with X‐ALD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 1×
“It is caused by mutations in the ABCD1 gene (http://www.x-ald.nl), encoding a peroxisomal transmembrane protein named ALD protein (ALDP: OMIM 300371) (Mosser et al 1993).”
BackgroundFatty acid elongases in mammals: their regulation and roles in metabolism
JAKOBSSON, A., WESTERBERG, R., & JACOBSSON, A. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.01.004 · Cited by 936
Moser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
Self-citationA Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242 · cited 1×
“Over the years several compounds have been investigated, such as Lorenzo’s oil (Aubourg et al 1993; van Geel et al 1999), 4-phenylbutyrate (Kemp et al 1998), and lovastatin (Engelen et al 2010; Singh et al 1998).”
BackgroundThe role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000061 · Cited by 170 · cited 12×
“We used purified microsomes from wild type and ELOVL1 over-expressing mice to test the effect of BF on elongation of both long-chain fatty acids (LCFA) and VLCFA.”
BackgroundInfluentialSelf-citationAnalysis of very long-chain fatty acids using electrospray ionization mass spectrometry
Valianpour, F., Selhorst, J. J. M., van Lint, L. E. M., van Gennip, A. H., Wanders, R. J. A., & Kemp, S. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00098-2 · Cited by 150 · cited 2×
“Stock solutions in DMSO were made of 400 mM (BF and clofibrate), 50 mM (fenofibrate), 10 mM (WY14643 and rosiglitazone), 500 μM (GW501516).”
BackgroundMethodSelf-citationNetik, A., Forss-Petter, S., Holzinger, A., Molzer, B., Unterrainer, G., & Berger, J. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.907 · Cited by 148
Biochemical aspects of X-linked adrenoleukodystrophy
Kemp, S., & Wanders, R. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00391.x · Cited by 116 · cited 1×
“The rate limiting enzymes involved in synthesis of C26:0 from C16:0 are ELOVL6 (elongation of C16:0 to C22:0) and ELOVL1 (elongation of C22:0 to C26:0) (Kemp and Wanders 2010; Ofman et al 2010).”
BackgroundSelf-citationKemp, S., Theodoulou, F. L., & Wanders, R. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01435.x · Cited by 115
Self-citationBerger, J., Albet, S., Bentejac, M., Netik, A., Holzinger, A., Roscher, A. A., Bugaut, M., & Forss‐Petter, S. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00772.x · Cited by 106 · cited 4×
“In Mdr1-/- knockout mice induction of ALDRP and PMP70 in brain did occur, suggesting that fenofibrate is indeed cleared from the brain by Mdr1 (Berger et al 1999).”
BackgroundInfluentialKishimoto, Y., Moser, H. W., Kawamura, N., Platt, M., Pallante, S. L., & Fenselau, C. (1980) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(80)91182-1 · Cited by 79 · cited 1×
“The VLCFA which accumulate in X-ALD, are partly absorbed from the diet (Kishimoto et al 1980), but mostly result from endogenous synthesis through elongation of long-chain fatty acids (Tsuji et al 1981).”
BackgroundTSUJI, S., SANO, T., ARIGA, T., & MIYATAKE, T. (1981) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a133578 · Cited by 73 · cited 1×
“The VLCFA which accumulate in X-ALD, are partly absorbed from the diet (Kishimoto et al 1980), but mostly result from endogenous synthesis through elongation of long-chain fatty acids (Tsuji et al 1981).”
BackgroundALDP expression in fibroblasts of patients with X-linked adrenoleukodystrophy
Kemp, S., Mooyer, P. A. W., Bolhuis, P. A., van Geel, B. M., Mandel, J. L., Barth, P. G., Aubourg, P., & Wanders, R. J. A. (1996) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01799844 · Cited by 37
Self-citation
Cited by
Adrenoleukodystrophy—Neuroendocrine pathogenesis and redefinition of natural history
Kemp, S., Huffnagel, I. C., Linthorst, G. E., Wanders, R. J., & Engelen, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.90 · Cited by 275
Self-citationX-Linked Adrenoleukodystrophy: Pathogenesis and Treatment
Engelen, M., Kemp, S., & Poll-The, B.-T. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0486-0 · Cited by 187
Self-citationLoss-or gain-of-function mutations in ACOX1 cause axonal loss via different mechanisms
Chung, H.-L., Wangler, M. F., Marcogliese, P. C., Jo, J., Ravenscroft, T. A., Zuo, Z., Duraine, L., Sadeghzadeh, S., Li-Kroeger, D., Schmidt, R. E., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.02.021 · Cited by 154
Chung, H.-L., Ye, Q., Park, Y.-J., Zuo, Z., Mok, J.-W., Kanca, O., Tattikota, S. G., Lu, S., Perrimon, N., Lee, H. K., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.022 · Cited by 70
Functional Characterization of IPSC-Derived Brain Cells as a Model for X-Linked Adrenoleukodystrophy
Baarine, M., Khan, M., Singh, A., & Singh, I. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143238 · Cited by 38
“fibroblasts, monocytes and lymphocytes) [27,33,45,46] and rodent primary or brain cell lines [16,29,31,33,47–50].”
Background
Metadata
- Authors
- Engelen, M., Schackmann, M. J. A., Ofman, R., Sanders, R., Dijkstra, I. M. E., Houten, S. M., Fourcade, S., Pujol, A., Poll‐The, B. T., Wanders, R. J. A., & Kemp, S.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2012-03-24
- Volume
- 35
- Issue
- 6
- Pages
- 1137-1145
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2052147460
- Cited by
- 48
- References
- 14
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.